secwatch.observer — SEC 8-K summary
======================================

Issuer:     Adaptimmune Therapeutics PLC (—)
CIK:        0001621227
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001104659-25-043522
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Adaptimmune transfers listing to Nasdaq Capital Market; gets 180-day extension to regain $1.00 bid
--------------------------------------------------------------------------------

- Approval to transfer ADS listing from Nasdaq Global Select to Nasdaq Capital Market, effective May 2, 2025.
- ADSs non-compliant with $1.00 minimum bid price since Nov 1, 2024; 180-day extension now runs to Oct 27, 2025.
- To regain compliance, ADS bid price must be at least $1.00 for 10 consecutive business days within extended period.
- Failure to comply by Oct 27, 2025 may result in delisting from Nasdaq.
- Company monitors bid price and will evaluate actions to satisfy Listing Rule 5450(a)(1).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925043522/0001104659-25-043522-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1621227/000110465925043522/tm2513768d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-043522

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer